Japanese Pharma Companies Turning to CDMOs Earlier in Product Life Cycle

The bottleneck isn’t discovery anymore. It’s execution. In peptides, programs are running into challenges around analytical complexity, scaleup, and the availability of key raw materials such as protected amino acids. The post Japanese Pharma Companies Turning to CDMOs Earlier in Product Life Cycle appeared first on GEN - Genetic Engineering and Biotechnology News .